Cue biopharma welcomes industry veteran mr. patrick verheyen to its board of directors

Boston, april 12, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today the appointment of industry veteran patrick verheyen to its board of directors (bod). mr. verheyen brings to cue biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at janssen pharmaceutical companies of johnson and johnson.
CUE Ratings Summary
CUE Quant Ranking